ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025
CDK4/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists' perceptions.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and Safety of Dalpiciclib in HR-Positive Advanced Breast Cancer: A Two-Center Retrospective Study.Cancers · 2026Article
- CDK4/6 inhibitors in breast cancer therapy: mechanisms of drug resistance and strategies for treatment.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in routine clinical practice in Spain, as well as the perceptions from oncologists.
methodsA survey was developed by nine oncologists, experts in breast cancer, practising in Spain. Survey responses were collected between July 2022 and April 2023.
resultsFifty-one survey responses were obtained. Most oncologists used CDK4/6 inhibitors in the first line. The first-line endocrine therapy most frequently used was an aromatase inhibitor (endocrine-sensitive disease) and fulvestrant (endocrine-resistant disease). CDK4/6 inhibitors were used for primary or secondary resistance, or visceral disease without visceral crisis. A lower-than-standard starting dose was considered (57% of respondents) for specific profiles. Strategies to manage toxicity included switching to another CDK4/6 inhibitor or delaying the next dose. CDK4/6 inhibitors were mostly considered to improve quality of life.
conclusionsUse of CDK4/6 inhibitors in Spain follows current recommendations and aligns with the evidence.
Indexed as
Identifiers
40146417What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.